GLPwatch
Ozempic for Anxiety
semaglutide · Investigational / off-label
Last updated 2026-05-28 15:46 UTCOzempic (semaglutide) is not FDA-approved for treating anxiety, and any use for this condition is off-label or investigational. Some research suggests potential effects on mood or anxiety-related behaviors, but findings are mixed and not conclusive for clinical use.
AI summary of the sources below.
| Drug | Ozempic (semaglutide) |
|---|---|
| Condition | Anxiety |
| Approval status | Investigational / off-label |
| Research papers | 13 |
Ozempic is not FDA-approved for anxiety; the research below reflects investigational or off-label study only.
Research on semaglutide for anxiety (13)
- Association of semaglutide with risk of suicidal ideation in a real-world cohort.
- Disproportionality Analysis From World Health Organization Data on Semaglutide, Liraglutide, and Suicidality.
- Psychiatric Safety of Semaglutide for Weight Management in People Without Known Major Psychopathology: Post Hoc Analysis of the STEP 1, 2, 3, and 5 Trials.
- Psychiatric adverse events associated with semaglutide, liraglutide and tirzepatide: a pharmacovigilance analysis of individual case safety reports submitted to the EudraVigilance database.
- Semaglutide Attenuates Anxious and Depressive-Like Behaviors and Reverses the Cognitive Impairment in a Type 2 Diabetes Mellitus Mouse Model Via the Microbiota-Gut-Brain Axis.
- Semaglutide in Psychiatry-Opportunities and Challenges.
- Psychiatric and psychological adverse effects associated with dulaglutide, semaglutide, and liraglutide: A vigibase study.
- Beyond Diabetes: Semaglutide's Role in Modulating Mood Disorders through Neuroinflammation Pathways.
- Semaglutide and risk of suicidal ideations.
- Semaglutide: A New Medical Swiss Army Knife?
- Clustering of intuitive eating and psychological health identifies subgroups associated with weight loss following semaglutide.
- [Effects of semaglutide on mental health].
- Semaglutide Linked With Lower Risk of Suicidal Thoughts.